A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

This is a multicenter, open-label study to evaluate single-agent brentuximab vedotin
(SGN-35) treatment in patients who previously participated in a brentuximab vedotin study,
including Studies SGN35-005 (NCT01100502), SGN35-007 (NCT01026233), and SGN35-008
(NCT01026415). Patients treated on this study (SGN35-006) could re-enroll on study if
eligible. The study consisted of 2 arms, as follows:

- Retreatment arm: Patients with CD30-positive hematologic malignancies who experienced a
complete remission (CR) or partial remission (PR) with previous brentuximab vedotin
treatment on a clinical study and subsequently experienced disease progression or
relapse. The purpose of this arm was to assess safety and efficacy of retreatment with
brentuximab vedotin.

- Extension treatment arm: Patients with either CD30-positive hematologic or
nonhematologic malignancies who completed treatment in a prior brentuximab vedotin
study without unacceptable toxicity and experienced clinical benefit as assessed by the
investigator. The purpose of this arm was to enable patients who participated in
certain prior brentuximab vedotin trials to receive extension treatment and to assess
patient safety and survival in the extension treatment setting.

Inclusion Criteria:

- Participated in a previous brentuximab vedotin study.

- CD30-positive hematologic malignancy.

- At a minimum, experienced clinical benefit in the prior brentuximab vedotin study.
For retreatment, patients must have previously achieved either complete or partial
remission with brentuximab vedotin and experienced disease progression after
discontinuing the prior brentuximab vedotin study.

Exclusion Criteria:

Withdrew consent to participate in any prior brentuximab vedotin study.